Please login to the form below

Not currently logged in
Email:
Password:

Repligen

This page shows the latest Repligen news and features for those working in and with pharma, biotech and healthcare.

Biogen buys into Ionis' nusinersen after positive phase III trial

Biogen buys into Ionis' nusinersen after positive phase III trial

Other companies working on therapies for SMA includeand Pfizer/Repligen.

Latest news

  • Pfizer acquires spinal muscular atrophy research programme Pfizer acquires spinal muscular atrophy research programme

    Pfizer acquires spinal muscular atrophy research programme. Gains rights to drug candidate RG3039 in deal with Repligen that could be worth up to $70m. ... $5m. The main candidate involved in the programme is RG3039, which will undergo phase I trials

  • Oncology bias in pharma deals

    112. Syntaxin/Ipsen. Research and development collaboration. Botulinum toxins. 99. Novozymes Biopharma Sweden/Repligen Corp.

  • Repligen bipolar drug fails in study

    Repligen bipolar drug fails in study. An oral form of uridine being developed by Repligen as a potential treatment for bipolar depression failed to show efficacy in a late-stage clinical ... trial. An oral form of uridine being developed by Repligen as a

  • State of mind

    Bayer. Acute mania. Armodafinil. Nuvigil; Cephalon. Bipolar disorder. RG 2417. Repligen. ... RG 2417 (Repligen) is a mitochondrial function enhancer based on uridine.

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Pharma deals during January 2013 Pharma deals during January 2013

    Repligen announced the signature of an exclusive worldwide licensing agreement with Pfizer to advance Repligen's spinal muscular atrophy (SMA) programme. ... Acquisition. Antibody manufacturer. 70. Repligen / Pfizer. Licence. RG3039 orphan for spinal

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics